Prophylactic treatment in Sweden--overtreatment or optimal model?
At the haemophilia centre in Malmö, Sweden, regular prophylactic treatment is begun at 1-1 1/2 years of age, before the onset of joint bleeds. The dose and dose interval are optimised by means of pharmacokinetic studies to determine the individual patient's FVIII or IX metabolism, the goal of maintaining a level > 1% of normal being taken as a guideline which experience has shown to yield satisfactory control of bleeding diathesis. An optimal model for prophylactic treatment needs to be applicable to haemophiliacs and acceptable to health authorities in a majority of the countries in the world. To fulfill these criteria, the Swedish model, which has been shown to yield most satisfactory outcome, can hopefully be further refined in the future. Were continuous infusion, using a recombinate concentrate with a prolonged half-life, technically feasible and socially acceptable to the child, we would probably have attained the optimal model of prophylactic treatment.
Ljung
R C
RC
Department of Paediatrics, University of Lund, University Hospital, Malmö, Sweden. Rolf.Ljung@pediatrik.mas.lu.se
D000293:Adolescent; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D005164:Factor IX / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005169:Factor VIII / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006467:Hemophilia A / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D013548:Sweden
D005169:Factor VIII; D005164:Factor IX